A Test in Focus

Rondell P. Graham, M.B.B.S., gives an overview of this test available through Mayo Clinic Laboratories. He discusses when this testing should be ordered, how this testing improves upon previous testing approaches, what clinical action can be taken due to the results of this testing.

By Alyssa Frank • June 12, 2019

Patients with autoimmune myelopathy present with subacute onset and rapid progression of spinal cord symptoms (weakness, gait difficulties, loss of sensation, neuropathic pain, and bowel and bladder dysfunction). Autoimmune myelopathy evaluation of serum and spinal fluid can assist in the diagnosis and aid distinction from other causes of myelopathy (multiple sclerosis, sarcoidosis, and vascular disease). Early diagnosis may assist in diagnosis of occult cancer, prompt initiation of immune therapies, or both.

By Alyssa Frank • June 12, 2019

The standard test for the diagnosis of narcolepsy is the multiple sleep latency test (MSLT). The MSLT is a complex test to perform as well as to interpret. The orexin-A/hypocretin-1 test is a sensitive and specific alternative to the MSLT to diagnose type 1 narcolepsy.

By Alyssa Frank • May 31, 2019

Joseph Yao, M.D., gives an overview of this new test available through Mayo Clinic Laboratories. He discusses when this testing should be ordered, how this testing improves upon other testing approaches, and what clinical action can be taken due to the results of this testing.

By Alyssa Frank • May 8, 2019

The diagnosis of mitochondrial disease can be particularly challenging as the presentation can occur at any age, involve virtually any organ system, and be associated with widely varying severities. Due to the considerable overlap in the clinical phenotypes of various mitochondrial disorders, it is often difficult to distinguish these specific inherited disorders without genetic testing.

By Alyssa Frank • May 3, 2019

Joshua Bornhorst, Ph.D., gives an overview of the new Copeptin test available through Mayo Clinic Laboratories. He discusses when this testing should be ordered, how this testing improves upon previous testing approaches, and what clinical action can be taken due to the results of this testing.

By Alyssa Frank • April 18, 2019

Jeffrey (Jeff) Meeusen, Ph.D., gives an overview of the new nuclear magnetic resonance (NMR) lipoprotein profile available through Mayo Clinic Laboratories. He discusses when this testing should be ordered, how this testing improves upon previous testing approaches, and what clinical action can be taken due to the results of this testing.

By Alyssa Frank • March 22, 2019

Nikola Baumann, Ph.D., gives an overview of the new NASH-FibroTest available through Mayo Clinic Laboratories. She discusses when this testing should be ordered, how this testing improves upon previous testing approaches, and what clinical action can be taken due to the results of this testing.

By Alyssa Frank • March 18, 2019

David Viswanatha, M.D., gives an overview of the NGS testing for myeloid malignancies available through Mayo Clinic Laboratories. He discusses when this testing should be ordered, how this testing improves upon previous testing approaches, and what clinical action can be taken due to the results of this testing.

By Alyssa Frank • February 14, 2019

Ann Moyer, M.D., Ph.D., gives an overview of the inflammatory bowel disease primary immunodeficiency testing available through Mayo Clinic Laboratories. She discusses when this testing should be ordered, how this testing improves upon previous testing approaches, and what clinical action can be taken due to the results of this testing.

By Emily Linginfelter • February 5, 2019

John Lieske, M.D., gives an overview of the phospholipase A2 receptor antibodies testing available through Mayo Clinic Laboratories. He discusses when this testing should be ordered, how this testing improves upon previous testing approaches, and what clinical action can be taken due to the results of this testing.

By Alyssa Frank • January 18, 2019

Christopher Klein, M.D., and Erik Thorland, Ph.D., give an overview of the new hereditary epilepsy panels available through Mayo Clinic Laboratories. They discuss the Mayo Clinic testing approach, interpretation and results, and custom gene ordering.

By Alyssa Frank • December 4, 2018

David Murray, M.D., Ph.D., provides an overview of the updated monoclonal gammopathy screening and monitoring tests for multiple myeloma. He discusses when this testing should be ordered, how this approach improves upon previous methods, and what clinical action can be taken from the results of these tests.

By Alyssa Frank • November 28, 2018